Gallstones are a prevalent health issue, with established risk factors such as diet body mass index (BMI) and physical activity. However, the role of Life's Essential 8 (LE8), a composite measure of health behaviors and biological markers, in predicting gallstone risk remains unclear. This study aims to examine the association between LE8 scores and gallstone prevalence in a U.S. adult population. A cross-sectional analysis was conducted on 2836 adults. LE8 scores were categorized into tertiles, and multivariable logistic regression models assessed the relationship between LE8 and gallstones, with additional nonlinear assessment using restricted cubic spline analysis. Gallstones prevalence was 10.37%, decreasing with higher LE8 scores. The multivariable analysis showed participants in higher LE8 tertiles had significantly lower gallstone risks compared to the lowest tertile. The spline analysis confirmed a significant nonlinear inverse association between LE8 and gallstone risk. Higher LE8 scores correlate with a lower prevalence of gallstones, suggesting the potential of LE8 as a predictor of gallstone risk. This emphasizes the value of promoting LE8 components in public health initiatives to reduce gallstone prevalence and medical burden.
24 September 2025 in Diabetology & Metabolic Syndrome
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent metabolic condition lacking sensitive and accessible biomarkers for early detection and risk stratification. To investigate the association between serum alpha-1-acid glycoprotein (AGP) levels and MAFLD prevalence among young and middle-aged women, and to evaluate the dose–response relationship and diagnostic performance of AGP. Data were obtained from 2,003 female participants aged 20–49 years in the NHANES 2017–2020 cycles. Weighted multivariable logistic regression models assessed the association between AGP and MAFLD, with adjustments for demographic, metabolic, and inflammatory covariates. Restricted cubic spline (RCS) regression evaluated nonlinear trends, and ROC analysis assessed predictive accuracy. Higher AGP levels were significantly associated with increased MAFLD risk. In the fully adjusted model, the highest AGP tertile had an odds ratio of 2.63 (95% CI: 1.65–4.19) compared to the lowest. RCS analysis showed a nonlinear, biphasic relationship with an inflection point around 0.9 g/L. ROC analysis indicated moderate discriminatory ability (AUC = 0.734), with AGP outperforming traditional liver enzymes. Subgroup analyses confirmed consistency across metabolic risk strata. AGP is independently and nonlinearly associated with MAFLD and may serve as a non-invasive biomarker for early identification of at-risk individuals. These findings support the potential clinical utility of AGP in MAFLD screening and risk assessment.
Epstein–Barr virus-positive inflammatory follicular dendritic cell sarcoma (EBV+ IFDCS) is a rare tumor that typically arises in the liver or spleen and is characterized by spindle-shaped cells within a dense lymphoplasmacytic background. We report a case of a 64-year-old woman with an incidental splenic mass found during routine imaging. MRI showed a 4.8 cm lesion with progressive enhancement. The patient underwent laparoscopic partial splenectomy. Histopathological examination revealed features consistent with EBV+ IFDCS, including positivity for CD21, CD23, CD35, SMA, EMA, and EBER. EBV+ IFDCS often presents with nonspecific symptoms and imaging findings, making diagnosis challenging. Definitive diagnosis relies on histology, immunohistochemistry, and confirmation of EBV infection. Most cases follow an indolent clinical course and have a favorable prognosis after complete surgical resection, though rare aggressive cases have been reported. Understanding its clinicopathological and molecular features is essential for accurate diagnosis and management.
Intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) is a rare biliary tumor with marked heterogeneity. We report two cases of unresectable IPMN-B, both treated with gemcitabine plus oxaliplatin (Gemox)-based hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and surufatinib. According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), calculated using the longest diameter of the target lesion, case 1 achieved radiographic stable disease (SD) and improvement in laboratory indices after two cycles of HAIC combined with targeted immunotherapy, followed by one cycle of maintenance therapy with tislelizumab plus surufatinib. Case 2 achieved radiographic partial response (PR) after four cycles of treatment, accompanied by marked improvement in abdominal pain and cholestatic indices. No severe treatment-related adverse events occurred in either patient, and both remained alive at the last follow-up. To place these observations in the context of existing evidence, we further reviewed the epidemiology, clinical manifestations, pathological and imaging features, treatment strategies, and prognosis of IPMN-B based on the available literature. These two cases suggest that multimodal combination therapy may have potential value in unresectable IPMN-B, although the durability of response, long-term safety, and the subgroups most likely to benefit still require further study.